Nebula Research & Development LLC Recursion Pharmaceuticals, Inc. Transaction History
Nebula Research & Development LLC
- $852 Billion
- Q4 2024
A detailed history of Nebula Research & Development LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 37,046 shares of RXRX stock, worth $204,123. This represents 0.03% of its overall portfolio holdings.
Number of Shares
37,046
Previous 36,244
2.21%
Holding current value
$204,123
Previous $239 Million
4.85%
% of portfolio
0.03%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding RXRX
# of Institutions
341Shares Held
285MCall Options Held
2.83MPut Options Held
3.64M-
Vanguard Group Inc Valley Forge, PA34MShares$187 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$178 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$137 Million0.13% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$95.4 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$80.8 Million0.44% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $994M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...